

## Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®

**Iconovo AB (publ), which develops complete inhalation products for a global market, and Affillogic (Nantes, France) today announce that Iconovo will present positive results from a feasibility study with a Nanofitin®-based biologic drug against respiratory virus using ICOone®. The study is a part of the previously communicated feasibility agreement between the companies, aimed at developing a new treatment for lung diseases. The study results will be presented at Respiratory Drug Delivery (RDD®) 2024, which takes place in Tucson, Arizona, on May 5-9, 2024.**

The current study assessed the feasibility of delivering Affillogic's anti-viral affinity proteins – Nanofitins® – against SARS-CoV-2 to the lung using Iconovo's dry powder single-dose inhaler ICOone®. Results confirmed that Nanofitins® can be formulated as a spray-dried powder for inhaled delivery and delivered by ICOone® with maintained activity and a fine particle fraction suitable for pulmonary delivery.

“We are very pleased with the results showing that Nanofitins can be delivered successfully to the lung using ICOone®. This possibility broadens the horizon to include new and innovative treatment strategies against viral and bacterial infections with the potential to play an important role in future pandemic response,” says Johan Wåborg, CEO of Iconovo.

“Our Nanofitins® are 20 times smaller than antibodies, highly soluble and extremely stable proteins, we anticipated that formulating them for inhalation would be feasible but we did not expect Iconovo's results with ICOone® to be so convincing from the very first test” says Olivier Kitten, CEO of Affillogic. “They really pave the way for the straightforward development of Nanofitin®-based inhaled targeted therapies”.

The results will be presented in full in a poster with the title “Novel inhaled anti-viral against SARS-CoV-2: Feasibility of developing a Nanofitin dry powder formulation for pulmonary delivery using the ICOone® single dose dry powder inhaler”, at the conference Respiratory Drug Delivery, RDD 2024 May 5-9, in Tucson, Arizona.

### **About RDD 2024**

Respiratory Drug Delivery (RDD®) 2024 will be held at the JW Marriott Starr Pass, Tucson, Arizona, from May 5-9, 2024. This is the latest Respiratory Drug Delivery conference in a series that has run continuously since 1988 and garnered a sustained reputation for excellent content covering all aspects of drug delivery to the lungs and nose. In-depth presentations and discussion of pioneering science in tandem with exceptional networking opportunities will appeal to scientists, engineers, regulators, clinicians, solutions providers, and business professionals active in this exciting field.

### **About Nanofitins®**

For any biological target, from peptides to entire cells, it is possible to generate custom Nanofitins® with a high binding affinity and controlled specificity for targeting or interacting purposes. They can thereby be designed as targeted inhibitors, mostly as a fusion of several Nanofitins® for multispecificity, or as vectors for specific transport of a third-party molecule (experience with enzymes, peptides, nanoparticles, radionuclides, cytotoxic payload, nucleic acids, CAR-T). Usual systemic routes can be traveled by Nanofitins® but their intrinsic properties make them amenable to other routes, such as pulmonary delivery.

### **About Affillogic**

Affillogic is an independent private company established in Nantes, France, and specialized in the discovery,

development and combinations of affinity proteins named Nanofitins® as biotherapeutics through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector. For more information, please visit <https://affilogic.com>

## Contacts

---

### **Johan Wäborg, CEO**

+46 707 78 51 71

[johan.waborg@iconovo.se](mailto:johan.waborg@iconovo.se)

## About Iconovo

---

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Carnegie Investment Bank AB (publ).

## Attachments

---

[Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®](#)